// March 01, 2024
Innovating for Individual Care: The Impact of USP on Personalized Medicine
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
Revised on: January 17, 2023
Persistent and long-lasting shortages of childhood cancer treatments undermine the advancements i
USP’s success in its mission to improve global public health through creation o